Vivani Medical Inc
NASDAQ:VANI

Watchlist Manager
Vivani Medical Inc Logo
Vivani Medical Inc
NASDAQ:VANI
Watchlist
Price: 1.4305 USD -0.66%
Market Cap: 79m USD
Have any thoughts about
Vivani Medical Inc?
Write Note

Vivani Medical Inc
Inventory

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Vivani Medical Inc
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
Vivani Medical Inc
NASDAQ:VANI
Inventory
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Inventory
$3.8B
CAGR 3-Years
10%
CAGR 5-Years
8%
CAGR 10-Years
10%
Boston Scientific Corp
NYSE:BSX
Inventory
$2.8B
CAGR 3-Years
20%
CAGR 5-Years
12%
CAGR 10-Years
11%
Stryker Corp
NYSE:SYK
Inventory
$5.3B
CAGR 3-Years
16%
CAGR 5-Years
10%
CAGR 10-Years
12%
Abbott Laboratories
NYSE:ABT
Inventory
$6.8B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
10%
Intuitive Surgical Inc
NASDAQ:ISRG
Inventory
$1.5B
CAGR 3-Years
36%
CAGR 5-Years
21%
CAGR 10-Years
22%
No Stocks Found

Vivani Medical Inc
Glance View

Market Cap
79m USD
Industry
Health Care

Vivani Medical Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Emeryville, California and currently employs 15 full-time employees. The company went IPO on 2014-11-19. Vivani Medical, Inc., formerly Second Sight Medical Products, Inc., is a developer of implantable visual prosthetics that creates an artificial form of useful vision for blind individuals. The firm is the combination of Nano Precision Medical, Inc. (NPM) and Second Sight Medical Products, Inc. NPM is a biopharmaceutical business that develops miniaturized, subdermal drug implants utilizing its NanoPortal technology to enable long-term, near constant-rate delivery of medicines to treat chronic diseases. Its divisions include Drug Implant & Visual Protheses division. The firm's Drug Implant division is developing a portfolio of miniature drug implants which utilize its NanoPortal drug implant technology. Its lead product, NPM-119, is a GLP-1 receptor agonist under development to treat patients with type two diabetes. The firm's Visual Protheses division is developing implantable visual prostheses devices that are intended to deliver useful artificial vision to blind individuals.

VANI Intrinsic Value
0.4516 USD
Overvaluation 68%
Intrinsic Value
Price

See Also

Back to Top